PDS Biotechnology Corporation (FRA:EU6)

Market Cap	40.92M
Revenue (ttm)	n/a
Net Income (ttm)	-29.73M
Shares Out	n/a
EPS (ttm)	-0.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,200
Average Volume	2,909
Open	0.7230
Previous Close	0.6475
Day's Range	0.7230 - 0.7230
52-Week Range	0.6085 - 2.0940
Beta	n/a
RSI	54.44
Earnings Date	Mar 26, 2026

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company’s lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protei...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EU6

Financial Performance

Financial numbers in USD